Siemens will host a complimentary Webinar, “Serum HER-2/neu in Breast Cancer,” on October 26. Tricia A. Bal, MD, MBA, Siemens Healthcare Diagnostics, will speak during the event.
The Webinar will cover the clinical utility of serum HER-2/neu, a simple blood test available on the ADVIA Centaur systems used to measure circulating HER-2 protein levels in metastatic breast cancer patients. Monitoring serum HER-2/neu levels yields important information about response to therapy and cancer progression, and may help physicians make more informed decisions when developing and modifying patient treatment regimens.
Attendees will discover how the Serum HER-2/neu test can indicate whether metastatic breast cancer is progressing or responding to treatment; review recent literature analyzing the value of serum HER-2/neu in clinical management; and examine patient cases demonstrating how serum HER-2/neu levels chronicle changes in disease.
This program has been designated for 1.0 PACE continuing education credit.
Source: Siemens
